24/7 Wall Street
24 Jun 2026, 20:33 UTC · 2h ago
Why I Can't Stop Buying This Unstoppable Dividend Juggernaut
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
24/7 Wall Street
24 Jun 2026, 20:33 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
AbbVie raised its full-year adjusted EPS guidance to a range of $14.08 to $14.28. — Upward revisions to earnings guidance typically trigger immediate positive price action and signal management confidence.
+0.60Skyrizi and Rinvoq revenues grew 30.9% and 23.3% respectively in Q1 2026, offsetting a 38.6% decline in Humira sales. — Direct evidence that the company is successfully replacing its primary revenue driver (Humira) with next-generation products.
+0.50AbbVie's Q1 2026 total revenue reached $15.00 billion, representing a 12.4% year-over-year increase. — Strong top-line growth and a beat over consensus estimates support a bullish valuation thesis.
+0.40Continue reading
6 related stories
Top 3 movers · tap to explore
The company has maintained a 52-year history of consecutive dividend increases, with the most recent increase occurring in January 2026. — Consistent dividend growth attracts a stable base of income investors and provides a valuation floor.
Imbruvica sales fell 24.7% in the quarter and the company carries negative shareholders' equity due to buybacks and acquisitions. — Declining sales in other drug lines and a leveraged balance sheet introduce long-term risk and potential volatility.
-0.30Which stocks this story touches
Strong growth in immunology drugs Skyrizi and Rinvoq, a consistent dividend history, and raised full-year EPS guidance.
Mentioned in the context of a recent 13% selloff and uncertainty regarding upcoming earnings.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
20m ago
